DFTX: Oppenheimer Raises Target
Oppenheimer maintains Outperform rating on Definium Therapeutics and raises price target to $60
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.